

Association between P53, Transforming Growth Factor Beta-1, and Interleukin-10 Serum Levels with Advanced Liver Disease and Hepatitis B Virus Infection

by Citrawati Dyahkencono Wungu

Submission date: 11-Oct-2021 08:08AM (UTC+0800)

Submission ID: 1670397167

File name: with_Advanced_Liver_Disease_and_Hepatitis_B_Virus_Infection.pdf (759.85K)

Word count: 3794

Character count: 20618

Associations between P53, Transforming Growth Factor Beta-1, and Interleukin-10 Serum Levels with Advanced Liver Disease and Hepatitis B Virus Infection

Citrawatidyahkencono Wungu^{1,2}, Mochamad Amin², Ulfa Kholili³, Gwennyichsan Prabowo¹, Poernomoboedi Setiawan³, Soetjipto^{4,5}, Retno Handajani^{4,5}

¹Researcher, Department of Physiology and Medical Biochemistry, Medical Faculty of Universitas Airlangga, Jl. Prof. Dr. Moestopo 47, Surabaya, Indonesia, ²Researcher, Institute of Tropical Disease, Universitas Airlangga Campus C, Surabaya, Indonesia, ³Clinical Instructor, Department of Internal Medicine, Medical Faculty Of Universitas Airlangga - Dr. Soetomo General Hospital, Jl. Prof. Dr. Moestopo 6-8, Surabaya, Indonesia, ⁴Professor, Institute Of Tropical Disease, Universitasairlangga Campus C, Surabaya, Indonesia, ⁵Professor, Department of Physiology And Medical Biochemistry, Medical Faculty Of Universitas Airlangga, Jl. Prof. Dr. Moestopo 47, Surabaya, Indonesia

Abstract

Background. Hepatitis B infection can lead to advanced liver disease (ALD) which causes serious health problems. Several factors that are thought to play a role in advanced liver disease are P53, Transforming Growth Factor- β 1 (TGF- β 1), and Interleukin-10 (IL-10). Therefore, this study aimed to determine the association between P53, TGF- β 1, and IL-10 serum levels with ALD.

Methods. We collected 68 sera from patients with HBV infection. P53, TGF- β 1, and IL-10 serum levels were measured by ELISA. We also detected SNPs from P53 and TGF- β 1 genes to determine their associations.

Results and Conclusions: In this study, we obtained 41.18% CH patients and 58.82% ALD patients. Male patients outnumbered female in all groups. There was a significant relationship between serum P53 and TGF- β 1 levels with ALD ($p = 0.03$ and 0.01 , respectively), but not serum IL-10 levels. However, there was no significant relationship between SNP gene P53 and serum P53 levels nor between SNP gene TGF- β 1 and serum TGF- β 1 levels ($p = 0.73$ and 0.23 , respectively). Both P53 and TGF- β 1 serum levels can act as biomarkers of prognosis and target therapy for ALD patients.

Keywords: P53, Transforming Growth Factor Beta-1, interleukin-10, advanced liver disease, Hepatitis B Virus infection

Introduction

Hepatitis B Virus (HBV) infection is a global health problem, especially in developing countries^{1,2}. Untreated early HBV infection can lead to persistent chronic infection with manifestations ranging from asymptomatic to cirrhosis, decompensated liver disease, and hepatocellular carcinoma (HCC) in up to 40% of patients^{3,4}. Annually, 3% of patients with chronic hepatitis B develop liver cirrhosis and 5% develop decompensated liver disease. The main therapy for end-stage liver disease is liver transplantation, however, this treatment modality cannot be accessed by the majority

of patients⁴. Liver cirrhosis and HCC are advanced liver disease (ALD) conditions with complex molecular pathogenesis, involving the interactions of various cells and cytokines^{5,6}. Several factors that are thought to play a role in advanced liver disease are Transforming Growth Factor- β 1 (TGF- β 1), P53, and Interleukin-10 (IL-10).

TGF- β 1 is a cytokine that can trigger apoptosis and control cell growth, but on the other hand, this cytokine can cause the transition of Hepatic Stellate Cell (HSC) to myofibroblasts which stimulate extracellular matrix synthesis and inhibit its degradation^{7,8}. Chronic

inflammatory conditions cause hepatocytes to become resistant to the anti-tumor activity of TGF- β 1 and a change in the signaling pathway converts TGF- β 1 to be pro-fibrotic and pro-carcinogenic^{9,10}. Changes in TGF- β 1 levels play an important role in the pathogenesis of various diseases, including liver disease¹¹. TGF- β 1 is also suggested to be a more specific biomarker than Alpha Feto Protein (AFP) for HCC¹².

²⁶ P53 also plays an important role in the pathogenesis of ALD, as the gene can be defective and mutated in HBV infection^{13,14}. This protein acts as a regulator which suppresses the cell cycle and induced apoptosis, thus preventing carcinogenesis, including liver cancer. As P53 protein has an important role in the progression of ALD, its expression can be used to monitor and identify ALD at an early stage.^{13,15,16}

⁹ Interleukin-10 (IL-10) is a cytokine produced by macrophages and dendritic cells to inhibit the activation of these two cells. Experimental data from animal models and clinical data from patients suggest that IL-10 is involved in the development of liver injury¹⁷. Even though IL-10 inhibits the production of various inflammatory cytokines (Th1 cytokines), including IL-1, TNF, and IL-12¹⁸, it suppresses immune system against HBV infection (rolisaxena). IL-10 inhibits T cell activity, either directly or indirectly. The direct effect of IL-10 inhibition on T cells is by inhibiting their proliferation, functional differentiation, and activity, while the indirect inhibition is by reducing the molecular expression of presenting cell antigens, thus interfering with T cell maturation¹⁹.

To date, data regarding the relationship between TGF- β 1, P53, and IL-10 levels and the incidence of CLD in patients with chronic HBV infection, especially in the Indonesian population, are still limited. Several other studies also linked the Single Nucleotide Polymorphism (SNP)s of TGF- β 1 and P53 genes with the expression, even though this yield conflicting results²⁰⁻²³. Therefore, this study aimed to analyze the relationship between serum TGF- β 1, P53, and IL-10 levels and HBV-related advanced liver disease in the Indonesian population.

Materials and Methods

Sampling

This was a cross-sectional study that used 68 stored blood samples from chronically infected HBV patients. Samples were taken at Inpatient/Outpatient Clinics of Internal Medicine Department, Dr. Soetomo General Hospital, Surabaya, Indonesia in 2017 and stored in -80°C freezer at Hepatitis laboratory, Institute of Tropical Disease, Surabaya, Indonesia. Inclusion criteria were: Adult patients with chronic HBV infection (HBsAg was positive for more than 6 months), clinically stable, and never had Hepatitis B vaccination. Exclusion criteria were: HCV and HIV coinfection, diabetes mellitus/ autoimmune diseases. Patients were categorized into chronic hepatitis without ALD if there were no sign of liver cirrhosis or hepatocellular carcinoma through physical, laboratory, and radiologic examination, while they were categorized into ALD if liver cirrhosis or HCC was found.

² This study had received approval from the Ethical Committee of Faculty of Medicine, Universitas Airlangga, Surabaya (Ethical clearance No. 186/EC/KEPK/FKUA/2020). Informed consent was explained and voluntarily signed by participants beforehand, in accordance with the declaration of Helsinki.

Measurement of TGF- β 1, P53, and IL-10 serum levels. TGF- β 1 serum level was measured by: Human TGF- β 1 ELISA Kit with Catalog No: E-EL-H0110 (Elabscience Biotechnology Inc, USA) according to the manufacturer's instructions. P53 serum level was measured by: Human TP53 (Tumor Protein p53) ELISA Kit with Catalog No: E-EL-H0910 (Elabscience Biotechnology Inc, USA). IL-10 serum level was measured by: Human TGF- β 1 ELISA Kit with Catalog No: E-EL-H0103 (Elabscience Biotechnology Inc, USA). Optical Density for TGF- β 1, P53, and IL-10 were measured by Microplate Reader: iMark (Biorad) S/N 12908.

Host DNA Extraction

¹⁰ Host DNA was extracted using QIAamp DNA Extraction kit (Qiagen, Germany) Cat.No.51104 according to the manufacturer's instructions.

PCR-RFLP of TGF- β 1 and p53 Genes

PCR was carried out as our previous work²⁴. TGF- β 1 gene SNP was checked at locus -509, while P53

gene SNP was checked at codon 72. PCR products of TGF- β 1-509 SNP were incubated using DdeI, while p53 SNP used BstUI.

TGF- β 1 -509 SNP showed 120 bp (T allele), while wild type (C allele) showed 74 and 46 bp fragments. p53 codon 72 SNP showed 231 and 165 bp fragments (G allele), while wild type showed 396 bp (C allele).

Statistical Analysis

Associations between TGF- β 1, P53, and IL-10 with ALD were analyzed for each parameter by Mann-Whitney test, while the associations between SNPs of TGF- β 1 and P53 with their expression were analyzed by Kruskal Wallis test. A P-value < 0.05 following a

two-tailed analysis was considered to be statistically significant. All statistical analyses were performed using SPSS version 23.

Results

Characteristics of the participants

This study involved 68 participants with HBV infection, consisting of 41.18% CH patients and 58.82% ALD patients. Data summary regarding gender, mean \pm SD age and age range of the participants can be seen in Table 1. The youngest patients with HBV infection in this study were 16 years old and the oldest was 72 years old, with a mean age of 47 years. There were more males (79.41%) than females (20.59%). The age range of male patients in this study was not much different from that of women, with the mean value being almost the same.

Table 1. Characteristics of the participants

Characteristics	CH (n=28)	ALD (n=40)	Total (n=68)	P-value
Gender				
Female	7	7	14	0.55
Male	21	33	54	
Age, years	44.36 \pm 16.31	49.23 \pm 9.52	47.22 \pm 12.87	0.16
P53 SNP Genotype				
CC	9	8	17	0.17
CG	15	22	37	
GG	4	10	14	
Allele				
C	33	38	71	0.28
G	23	42	65	
TGF- β 1 SNP Genotype				
CC	8	8	16	0.44
CT	14	18	32	
TT	6	14	20	
Allele				
C	30	34	64	0.22
T	26	46	72	
P53 serum level (pg/mL)	114.99 \pm 164.73	244.75 \pm 374.62	191.32 \pm 311.07	0.03*
TGF- β 1 serum level (ng/mL)	0.16 \pm 0.39	0.29 \pm 0.27	0.21 \pm 0.35	0.01*
IL-10 serum level (pg/mL)	9.38 \pm 9.14	14.34 \pm 34	12.3 \pm 26.69	0.76

* statistically significant

In both CH and ALD, more patients were male than female, although there was no significant difference in gender distribution in the CH and ALD groups. From statistical analysis, there was no significant difference between gender and age with ALD. For both SNPs, heterozygote genotype were predominant in either CH or ALD. SNP analysis showed that there was no difference in the distribution of genotypes or SNP alleles of TGF- β 1 and p53 between CH and ALD. Serum P53, TGF- β 1, and IL-10 levels in ALD patients were higher than those of CH patients. There was a significant relationship between serum P53 and TGF- β 1 levels with ALD, but not serum IL-10 levels. However, there was no significant relationship between SNP gene P53 and serum P53 levels nor between SNP gene TGF- β 1 and serum TGF- β 1 levels $p = 0.73$ and 0.23 , respectively).

Discussion

In this study, 68 samples of patients with HBV infection were obtained, consisting of CH and ALD. The number of male patients were more than women. This is in accordance with several previous studies which stated that there were more people with cirrhosis of the liver with HBV infection in men than in women²⁵⁻²⁷. This is due to the protective role of estrogen for the liver. Estrogen can inhibit stellate cell proliferation and fibrogenesis which plays an important role in the course of cirrhosis. In experimental animal models with liver cirrhosis, administration of estradiol causes a decrease in collagen types I and III and proliferation of stellate cells.²⁸ Besides being able to reduce viral RNA transcription and HBx expression, estrogen is also able to regulate HBV activity through direct inhibition of the binding of Hepatocyte Nuclear Factor (HNF)-4 α with HBV EnhI, thus estrogen signals can suppress the production of pro-inflammatory cytokines in the liver^{29,30}. ALD patients in this study were dominated by the age range 45-50 years. It is said that the mean age of incidence of HCC associated with HBV infection is 50 years, except in high-risk populations which is 40 years³¹.

In this study, it was found that the levels of P53, TGF- β 1, and IL-10 were higher in men than women. Levels of P53, TGF- β 1, and IL-10 were also found to be higher in ALD than in CH. In statistical analysis, there

were significant differences in serum P53 and TGF- β 1 levels between the ALD and CH ($p < 0.05$). It was said that the expression of P53 increased in malignancy and pre-malignancy, even overexpression of P53 was not uncommon in malignant conditions, including in terms of it's in liver cancer. In liver cancer there may also be a mutation in the P53 gene that increases expression and cannot be distinguished from normal P53 expression³². TGF- β 1 levels also indicate hepatic function impairment, which is increasing in number in patients with cirrhosis of the liver. In the liver, high levels of TGF- β 1 play a role in the occurrence of hepatic fibrogenesis, regulation of cell growth, and tumor development.³³ In a study by Kohla et al (2017), it was also stated that TGF- β 1 levels increased with disease severity and progression in hepatocellular carcinoma, and TGF- β 1 level could be complementary to alpha fetoprotein (AFP) in the diagnosis of HCC.³⁴ In this study, there was no significant relationship between serum IL-10 levels and ALD. This is in line with the meta-analysis conducted by Shakiba et al (2018) which states that there are differences in IL-10 levels between HCC patients and normal people, but there is no difference between HCC and CH patients. In that study, it was also stated that the increase in IL-10 levels in ALD was due more to the cirrhosis process than tumor load³⁵.

When associated with previous studies, there was no relationship between Single Nucleotide Polymorphism (SNP) TGF- β 1 -509T/C and P53 Arg72Pro genes with TGF- β 1 and P53 serum levels. In vitro, it is known that there are several external factors that can influence the expression of the five TGF- β isoforms, including TGF- β 1. In addition, the TGF- β 1 signaling process is quite complex, involving the intracellular protein Smad which acts on various transcription factors in the nucleus. The expression of TGF- β 1 is also influenced by a variety of different cytokines and chemical compounds. Other locus polymorphisms such as C466T and T869C can also affect TGF- β 1 expression³⁶. Likewise, P53 levels are not only affected by the Arg72Pro polymorphism, but also SNPs in other P53 gene regions, including non-coding regions that can affect gene splicing³⁷.

This study has several limitations, the first, it did not compare between ALD and CH with healthy controls. The second, it could not explain the role of other cytokines and epigenetic pathways in relation to

the pathogenesis of ALD. Further research is needed to understand the mechanism pathways for increasing levels of P53 and TGF- β 1 in ALD patients other than through gene expression and polymorphisms. Studies regarding the various cytokines and molecular signaling involved can help understand the pathogenesis and are used as therapeutic pathways in ALD patients with HBV infection.

Conclusion

⁵ P53 and TGF- β 1 levels were significantly elevated in ALD patients with HBV infection. Both parameters can act as biomarkers of prognosis and target therapy for ALD patients.

² **Ethical approval:** Ethical Committee of Faculty of Medicine, Universitas Airlangga, Surabaya (Ethical clearance No. 186/EC/KEPK/FKUA/2020).

Patient' Informed Consent: Patient's informed consent has been obtained.

²⁴ **Conflict of Interest:** Nil

Funding

The authors would like to thank Universitas Airlangga for giving research fund through "Penelitian Unggulan Fakultas" year 2020.

References

1. Xu H-Z, Liu Y-P, Guleng B, Ren J-L. Hepatitis B Virus-Related Hepatocellular Carcinoma: Pathogenic Mechanisms and Novel Therapeutic Interventions. *Gastrointest Tumors* [Internet]. 2014;1(3):135–45. Available from: <http://www.karger.com?doi=10.1159/000365307>
2. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. 2015 Advances in Hepatitis B virus hepatitis B virus burden in developing countries. *World J Gastroenterol*. 2015;21(42):11941–53.
3. Weisberg IS, Brown RS, Sigal SH. Hepatitis B and End-Stage Liver Disease. *Clin Liver Dis*. 2007;11(4):893–916.
4. Guan R, Lui HF. Treatment of Hepatitis B in Decompensated Liver Cirrhosis. *Int J Hepatol* [Internet]. 2011;2011:1–11. Available from: <http://www.hindawi.com/journals/ijh/2011/918017/>
5. Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF- β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. *Cells*. 2019;8(11):1–35.
6. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. *World J Gastroenterol*. 2014;20(23):7312–24.
7. Bordiny M El, Hanafy SM, Abdo A. Impact of single nucleotide polymorphism of TGF- β 1 gene (SNP-Codon10) on hepatocellular carcinoma risk in Egyptian patients following HCV infection. *Aust J Basic Appl Sci*. 2011;5(9):1814–21.
8. Mohy A, Fouad A. Role of transforming growth factor- β 1 in serum and -509 C>T promoter gene polymorphism in development of liver cirrhosis in Egyptian patients. *Meta Gene* [Internet]. 2014;2:631–7. Available from: <http://dx.doi.org/10.1016/j.mgene.2014.08.002>
9. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, et al. TGF-Beta1 genotypes in cirrhosis: Relationship with the occurrence of liver cancer. *Cytokine*. 2008;44(2):256–61.
10. Ozaki I, Hamajima H, Matsuhashi S, Mizuta T. Regulation of TGF- β 1-induced pro-apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver. *Front Physiol*. 2011;2 OCT(October):1–8.
11. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma. *Hepatology*. 2007;46(1):48–57.
12. Yao D-F, Dong Z-Z, Yao M. Specific molecular markers in hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* [Internet]. 2007;6(3):241–7. Available from: <papers3://publication/uuid/E679ED79-36DF-452B-A23D-F0B4D180D28A>
13. Wang Z, Gou W, Liu M, Sang W, Chu H, Zhang W. Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study. *Med Sci Monit* [Internet]. 2015;21:3209–15. Available from: <http://www.medscimonit.com/abstract/index/idArt/895592>
14. Hussain SP, Schwank J, Staib F, Wang XW, Harris

- CC. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. *Oncogene*. 2007;26(15):2166–76.
15. Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, et al. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. *Carcinogenesis*. 2012;33(6):1219–24.
 16. Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: Evidence from a meta-analysis of 15 studies with 3,704 cases. *Tumor Biol* [Internet]. 2014;35(4):3647–56. Available from: <http://dx.doi.org/10.1016/j.mgene.2013.09.010>
 17. Knolle PA, Gerken G. Local control of the immune response in the liver. *pdfVN-readcube.com. Immunol Rev* [Internet]. 2000;174:21–34. Available from: [c:%5CUsers%5C Costr005%5C Desktop%5C Phd backups%5C Dell Backup 130701%5C DELL%5C PHD%5C O ther%5C R eview and Literature-PDFs%5C S ystematic R eview%5C PDFs for s ystematic r eview%5C M edline S earch%5C N OT A CCEPTED%5C E xcluded but i mportant%5C L ocal control of the immune res](http://cusers.cox.net/~cphd/backups/CDellBackup130701/CDell/CPHD/COther/SCReviewandLiteraturePDFs/CSystematicReview/CPDFsforSystematicReview/CMedlineSearch/SCNOTACCEPTED/CExcludedbutimportant/SCLocalcontroloftheimmuneresponseintheliver.pdf)
 18. Abbas AK, Lichtman AH, Pillai S, Baker DL, Baker A. *Cellular and Molecular Immunology*. 8th ed. Philadelphia: Elsevier Saunders; 2015.
 19. Özgüler M, Akbulut HH, Akbulut A. Evaluation of interleukin-10 levels in patients diagnosed with chronic hepatitis. *West Indian Med J*. 2015;64(2):71–5.
 20. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. *Cold Spring Harb Perspect Biol*. 2010;2(5):1–18.
 21. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. *Oncogene*. 2007;26(9):1317–23.
 22. Khani M, Amani D, Taheripanah R, Sanadgol N, Feizollahzadeh S, Rahmani Z. Transforming growth factor beta-1 (TGF- β 1) gene single nucleotide polymorphisms (SNPs) and susceptibility to pre-eclampsia in Iranian women: A case-control study. *Pregnancy Hypertens* [Internet]. 2015;5(4):267–72. Available from: <http://dx.doi.org/10.1016/j.preghy.2015.01.002>
 23. Xu S, Yang S, Sun G, Huang W, Zhang Y. Transforming Growth Factor-Beta Polymorphisms and Serum Level in the Development of Osteosarcoma. *DNA Cell Biol*. 2014;33(11):802–6.
 24. Wungu CDK, Amin M, Ruslan SEN, Purwono PB, Kholili U, Maimunah U, et al. Association between host TNF- α , TGF- β 1, p53 polymorphisms, hbv x gene mutation, hbv viral load and the progression of hbv-associated chronic liver disease in Indonesian patients. *Biomed Reports*. 2019;11(4):145–53.
 25. Bobek V, Kolostova K, Pinterova D, Kacprzak G, Adamiak J, Kolodziej J, et al. A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. *Anticancer Res*. 2010;30(12):4799–804.
 26. Lee MH, Kim DY, Kim JK, Chang HY, Kang SH, Ryu HJ, et al. Combination of preS deletions and A1762T/G1764A mutations in HBV subgenotype C2 increases the risk of developing HCC. *Intervirology*. 2012;55(4):296–302.
 27. Başıyigit S, Asiltürk Z, Sapmaz F, Kefeli A, Yeniova AÖ, Uzman M, et al. Hepatitis B virus is still the most common etiologic factor of liver cirrhosis: Results from a single center in Turkey. *Dicle Med J / Dicle Tıp Derg* [Internet]. 2015;42(4):416–21. Available from: <http://dergipark.gov.tr/doi/10.5798/diclemedj.0921.2015.04.0601>
 28. Brady CW. Liver disease in menopause. *World J Gastroenterol*. 2015;21(25):7613–20.
 29. Montella M, D’Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, et al. Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. *Int J Endocrinol*. 2015;2015:1–9.
 30. Wang SH, Yeh SH, Lin WH, Yeh KH, Yuan Q, Xia NS, et al. Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4 α . *Gastroenterology* [Internet]. 2012;142(4):989–998.e4. Available from: <http://dx.doi.org/10.1053/j.gastro.2011.12.045>
 31. Yan H, Yang Y, Zhang L, Tang G, Wang Y, Xue G, et al. Characterization of the Genotype and Integration Patterns of Hepatitis B Virus in Early- and Late-Onset Hepatocellular Carcinoma. *Hepatology*. 2015;61:1821–31.
 32. Lalisang TJM, Moenadjat Y, Siregar NC, Stephanie

- M. Overexpression of p53 in extra large (More than 10 cm) hepatocellular carcinoma. *Med J Indones.* 2018;27(2):3.
33. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor β 1 as an indicator of hepatic function impairment in liver cirrhosis. *Cytokine.* 2000;12(6):677–81.
34. Kohla MAS, Attia A, Darwesh N, Obada M, Taha H, Youssef MF. Association of serum levels of transforming growth factor b1 with disease severity in patients with hepatocellular carcinoma. *Hepatoma Res.* 2017;3(12):294.
35. Shakiba E, Sadeghi M, Shakiba M. A systematic review and meta-analysis of evaluation of serum interleukin 8 levels in hepatocellular carcinoma. *Clin Exp Hepatol.* 2019;5(2):123–8.
36. Panek M, Pietras T, Fabijan A, Zioło J, Wieteska Ł, Małachowska B, et al. Identification and association of the single nucleotide polymorphisms, C-509T, C+466T and T+869C, of the TGF-1 β gene in patients with asthma and their influence on the mRNA expression level of TGF- β 1. *Int J Mol Med.* 2014;34(4):975–86.
37. Zhang G, Xu Q, Wang Z, Sun L, Lv Z, Liu J, et al. P53 protein expression affected by TP53 polymorphism is associated with the biological behavior and prognosis of low rectal cancer. *Oncol Lett.* 2019;18(6):6807–21.

Association between P53, Transforming Growth Factor Beta-1, and Interleukin-10 Serum Levels with Advanced Liver Disease and Hepatitis B Virus Infection

ORIGINALITY REPORT

21 %
SIMILARITY INDEX

17 %
INTERNET SOURCES

19 %
PUBLICATIONS

1 %
STUDENT PAPERS

PRIMARY SOURCES

1 Wafa Khaali, Khalid Moumad, El Khalil Ben Driss, Abdellatif Benider et al. "No association between TGF- β 1 polymorphisms and risk of nasopharyngeal carcinoma in a large North African case-control study", BMC Medical Genetics, 2016 **1** %
Publication

2 Heny Arwati, Ramadhani R. Bahalwan, Windya T. Hapsari, Kartika A. Wardhani, Kholida N. Aini, Putu I. B. Apsari, Puspa Wardhani. "Suppressive effect of goat bile in Plasmodium berghei ANKA infection in mice", Veterinary World, 2021 **1** %
Publication

3 www.thieme-connect.com **1** %
Internet Source

4 bmcchem.biomedcentral.com **1** %
Internet Source

5	Internet Source	1 %
6	www.inabj.org Internet Source	1 %
7	e-journal.unair.ac.id Internet Source	1 %
8	repository.unair.ac.id Internet Source	1 %
9	www.science.gov Internet Source	1 %
10	jmhg.springeropen.com Internet Source	1 %
11	clonerresources.com Internet Source	1 %
12	doaj.org Internet Source	1 %
13	www.researchsquare.com Internet Source	1 %
14	jcmr-online.biomedcentral.com Internet Source	1 %
15	Submitted to Universitas Airlangga Student Paper	1 %
16	Mastroianni, Claudio, Miriam Lichtner, Claudia Mascia, Paola Zuccalà, and Vincenzo Vullo.	<1 %

"Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection", International Journal of Molecular Sciences, 2014.

Publication

17

clinicalstudies.info.nih.gov

Internet Source

<1 %

18

www.nice.org.uk

Internet Source

<1 %

19

www.ajol.info

Internet Source

<1 %

20

Chien Peter Chen, Daphne Haas-Kogan. "Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics", Expert Review of Molecular Diagnostics, 2014

Publication

<1 %

21

J. Jiwakanon, M. Berg, E. Persson, C. Fossum, A.-M. Dalin. "Cytokine expression in the gilt oviduct: Effects of seminal plasma, spermatozoa and extender after insemination", Animal Reproduction Science, 2010

Publication

<1 %

22

J. Zhao, Y. Liang, Q. Yin, S. Liu, Q. Wang, Y. Tang, C. Cao. "Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic

<1 %

ductal adenocarcinoma", Brazilian Journal of Medical and Biological Research, 2016

Publication

23

Timofeeva, O.A.. "Effects of o-aminoazotoluene on liver regeneration and p53 activation in mice susceptible and resistant to hepatocarcinogenesis", Toxicology, 20081205

Publication

<1 %

24

Galih Sampoerno, Jenny Sunariani, Kuntaman. "Expression of NaV-1.7, TNF- α and HSP-70 in experimental flare-up post-extirpated dental pulp tissue through a neuroimmunological approach", The Saudi Dental Journal, 2019

Publication

<1 %

25

bmccresnotes.biomedcentral.com

Internet Source

<1 %

26

doi.org

Internet Source

<1 %

27

journals.viamedica.pl

Internet Source

<1 %

28

pdfs.semanticscholar.org

Internet Source

<1 %

29

www.annclinlabsci.org

Internet Source

<1 %

30	"Clinical Epidemiology of Chronic Liver Diseases", Springer Science and Business Media LLC, 2019 Publication	<1 %
31	annalsgastro.gr Internet Source	<1 %
32	journals.lww.com Internet Source	<1 %
33	jurnal.permi.or.id Internet Source	<1 %
34	spandidos-publications.com Internet Source	<1 %
35	www.frontiersin.org Internet Source	<1 %
36	www.jpma.org.pk Internet Source	<1 %
37	www.labome.org Internet Source	<1 %
38	"Abstracts 639–838", Hepatology, 2010 Publication	<1 %
39	I Gusti Aju Wahyu Ardani, Ageng Wicaksono, Thalca Hamid. "	<1 %

The Occlusal Plane Inclination Analysis for Determining Skeletal Class III Malocclusion

Diagnosis

", Clinical, Cosmetic and Investigational Dentistry, 2020

Publication

40

Lili Liu. "Correlation between viral load and liver cirrhosis in chronic hepatitis B patients", Frontiers of Medicine in China, 07/29/2009

Publication

<1 %

41

Mohamed Ahmed Samy Kohla, Ahmed Attia, Nehad Darwesh, Manar Obada, Hossam Taha, Marwa F. Youssef. "Association of serum levels of transforming growth factor b1 with disease severity in patients with hepatocellular carcinoma", Hepatoma Research, 2017

Publication

<1 %

42

Ashraf A. Dawood, Amany A. Saleh, Osama Elbahr, Suzy Fawzy Gohar, Mona S. Habieb. "Inverse relationship between the level of miRNA 148a-3p and both TGF- β 1 and FIB-4 in hepatocellular carcinoma", Biochemistry and Biophysics Reports, 2021

Publication

<1 %

43

Masoud Karimi-Googheri, Hamid Daneshvar, Reza Nosratabadi, Mohammad Zare-Bidaki et al. "Important roles played by TGF- β in

<1 %

hepatitis B infection", Journal of Medical Virology, 2014

Publication

Exclude quotes On

Exclude matches Off

Exclude bibliography On

Association between P53, Transforming Growth Factor Beta-1, and Interleukin-10 Serum Levels with Advanced Liver Disease and Hepatitis B Virus Infection

GRADEMARK REPORT

FINAL GRADE

/100

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5

PAGE 6

PAGE 7
